Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAscendis Pharma A/S Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 7 | -$1.77 | -$1.19 | -$1.47 |
| Q2 2025 | 12 | -$1.88 | -$0.78 | -$1.29 |
| Q3 2025 | 10 | -$0.66 | $0.16 | -$0.24 |
| Q4 2025 | 9 | -$0.19 | -$0.06 | -$0.11 |
| Q1 2026 | 5 | $0.31 | $0.97 | $0.57 |
| Q2 2026 | 1 | $0.73 | $0.93 | $0.84 |
| Q3 2026 | 1 | $1.01 | $1.29 | $1.16 |
| Q4 2026 | 1 | $1.52 | $1.95 | $1.76 |
Ascendis Pharma A/S Earnings Date And Information
Ascendis Pharma A/S last posted its earnings results on Wednesday, November 12th, 2025. The company reported $-1.17 earnings per share for the quarter, missing analysts' consensus estimates of $-0.41 by $0.76. The company had revenue of 213.63 M for the quarter and had revenue of 363.64 M for the year. Ascendis Pharma A/S has generated $-7 earnings per share over the last year ($-6.53 diluted earnings per share) and currently has a price-to-earnings ratio of -39.3. Ascendis Pharma A/S has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based on prior year's report dates.
Ascendis Pharma A/S Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2025 | Q3 2025 | -$0.41 | -$1.00 | -0.59 | $213.64 M | $213.63 M |
| 08/07/2025 | Q2 2025 | -$1.42 | -$0.64 | 0.78 | $144.78 M | $158.05 M |
| 05/01/2025 | Q1 2025 | -$1.56 | -$1.58 | -0.02 | N/A | $100.95 M |
| 02/12/2025 | Q4 2024 | -$1.20 | -$0.64 | 0.56 | N/A | $173.92 M |
| 09/30/2024 | Q3 2024 | N/A | -$1.69 | N/A | $70.09 M | $57.83 M |
| 06/29/2024 | Q2 2024 | N/A | -$1.91 | N/A | $82.80 M | $36.00 M |
| 05/02/2024 | Q1 2024 | -$1.62 | -$2.30 | -0.68 | N/A | $95.89 M |
| 02/07/2024 | Q4 2023 | -$2.19 | -$1.53 | 0.66 | N/A | $137.70 M |
| 09/29/2023 | Q3 2023 | N/A | -$2.88 | N/A | $49.05 M | $48.03 M |
| 06/30/2023 | Q2 2023 | N/A | -$2.16 | N/A | $37.24 M | $47.39 M |
| 04/27/2023 | Q1 2023 | -$2.93 | -$1.98 | 0.95 | $21.50 M | $33.59 M |
| 02/16/2023 | Q4 2022 | -$2.74 | -$3.70 | -0.96 | $19.15 M | $22.90 M |
| 09/30/2022 | Q3 2022 | N/A | -$3.03 | N/A | $8.81 M | $15.29 M |
| 06/30/2022 | Q2 2022 | N/A | -$1.46 | N/A | $5.60 M | $6.16 M |
| 05/11/2022 | Q1 2022 | -$2.09 | -$2.21 | -0.12 | $4.55 M | $6.83 M |
| 03/02/2022 | Q4 2021 | -$2.57 | -$1.97 | 0.6 | $2.71 M | $4.90 M |
| 11/10/2021 | Q3 2021 | -$2.63 | -$1.47 | 1.16 | $1.14 M | $1.11 M |
| 08/26/2021 | Q2 2021 | N/A | -$2.50 | N/A | $746.43 K | $1.02 M |
| 03/31/2021 | Q1 2021 | N/A | -$1.17 | N/A | $1.64 M | $746.00 K |
| 12/31/2020 | Q4 2020 | N/A | -$2.60 | N/A | $1.69 M | $535.00 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Ascendis Pharma A/S Earnings: FAQ's
Ascendis Pharma A/S has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based offlast year's report dates.
The conference call for Ascendis Pharma A/S's latest earnings report can be listened to online.
The conference call transcript for Ascendis Pharma A/S's latest earnings report can be read online.
Ascendis Pharma A/S (:ASND) has a recorded annual revenue of $363.64 M.
Ascendis Pharma A/S (:ASND) has a recorded net income of $-378,084,000.Ascendis Pharma A/S has generated $-6.53 earnings per share over the last four quarters.
Ascendis Pharma A/S (:ASND) has a price-to-earnings ratio of -39.3 and price/earnings-to-growth ratio is -1.8.